Tharimmune, Inc., a leading biotechnology company specializing in inflammation and immunology therapies, is gearing up to showcase its groundbreaking innovations at the highly anticipated 2024 Emerging Growth Conference. The event, scheduled for March 7, 2024, will provide a platform for Tharimmune to present its latest advancements and engage with the investment community.

Randy Milby, the Chairman and CEO of Tharimmune, will lead the presentation, which will include an interactive Q&A session. This session offers shareholders and potential investors a valuable opportunity to delve into the company’s strategies, developments, and future directions.

Emerging Growth Conference: A Nexus of Innovation and Investment

The Emerging Growth Conference is known for its unique format that enables real-time interaction between companies and the global investment community. Set for March 7, 2024, the conference aims to showcase a diverse range of growth sectors and feature companies with strong leadership, innovative solutions, and a clear vision for long-term growth.

Tharimmune’s participation in the conference underscores its significant role in the biotechnology landscape, particularly in the development of therapies for inflammation and immunology. Randy Milby’s presentation at 10:15 am Eastern time will not only highlight the company’s achievements but also its commitment to addressing challenging medical conditions.

A Closer Look at Tharimmune’s Endeavors

Tharimmune’s flagship clinical-stage asset, TH104, is at the forefront of its efforts to combat chronic pruritus associated with Primary Biliary Cholangitis (PBC), a rare liver disease without a known cure. This innovative therapy offers hope for patients suffering from this debilitating condition, demonstrating Tharimmune’s dedication to making a tangible difference in the lives of those affected by rare diseases.

Besides TH104, Tharimmune’s early-stage pipeline features promising novel multi-specific antibodies designed to target and neutralize critical epitopes in solid tumors, including PD-1, HER2, and HER3 targets.